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Abstract
 
About 30% of cases of the autosomal recessive immunodeficiency disorder hemophagocytic
lymphohistiocytosis are believed to be caused by inactivating mutations of the perforin gene.
We expressed perforin in rat basophil leukemia cells to define the basis of perforin dysfunction
associated with two mutations, R225W and G429E, inherited by a compound heterozygote
patient. Whereas RBL cells expressing wild-type perforin (67 kD) efficiently killed Jurkat target
cells to which they were conjugated, the substitution to tryptophan at position 225 resulted in
expression of a truncated (
 
 
 
45 kD) form of the protein, complete loss of cytotoxicity, and failure
to traffic to rat basophil leukemia secretory granules. By contrast, G429E perforin was correctly
processed, stored, and released, but the rat basophil leukemia cells possessed reduced cytotoxicity.
The defective function of G429E perforin mapped downstream of exocytosis and was due to its
reduced ability to bind lipid membranes in a calcium-dependent manner. This study elucidates
the cellular basis for perforin dysfunctions in hemophagocytic lymphohistiocytosis and provides
the means for studying structure–function relationships for lymphocyte perforin.
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Introduction
 
Perforin, a membrane-disruptive protein secreted by cyto-
toxic T lymphocytes and natural killer cells (collectively
cytotoxic lymphocytes [CLs]), is essential for the death of
virus-infected or transformed cells targeted for destruction
through the granule exocytosis pathway (1–6). Perforin-
deficient mice and humans are severely immunosuppressed.
Perforin-null mice lack resistance to many viruses and intra-
cellular pathogens such as 
 
Listeria
 
 
 
monocytogenes
 
 (1). Their sup-
pression of many experimental metastases (7) and carcinogen-
induced tumors (8) is also deficient, and more than half
develop spontaneous, highly aggressive B cell lymphomas
as they age (9), indicating a fatal lapse of tumor immune
surveillance (10).
A syndrome of perforin deficiency was recently described
in humans, in that 
 
 
 
30% of immunodeficient children pre-
senting with the autosomal recessive disorder hemophago-
cytic lymphohistiocytosis (HLH) carry mutations in both
their perforin alleles (11–13). The CLs of these children are
unable to impart a lethal hit to target cells and thus fail to
clear APCs, resulting in uncontrolled activation and accu-
mulation of macrophages and overproduction of proinflam-
matory cytokines. Clinically, this is manifested as fever, liver
and spleen enlargement, and hemophagocytosis in the
spleen, liver, and bone marrow (14). The CLs of these
patients  show a marked reduction of perforin content,
which is thought to indicate failed expression, inaccurate
trafficking and/or instability of mutated perforin. Overall,
the clinical and pathological findings in HLH are strikingly
reminiscent of perforin-deficient mice infected with lym-
phocytic choriomeningitis virus, as these animals also show
expansion of T- and antigen-presenting cell numbers and
are unable to down-regulate the immune response (10).
Perforin is released from the secretory granules of CLs
with granzymes, a family of proapoptotic serine proteases,
and is thought to mediate their trafficking to the target cell
cytosol where the proteolytic activity of granzymes imposes
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apoptotic cell death (15). Purified perforin applied alone at
high concentration can also induce osmotic lysis, which
may also occur under some physiologically relevant condi-
tions (15). However, at the molecular and cellular levels
very little is known of how perforin achieves its functions.
This sizeable gap in our knowledge exists largely because it
has not been possible to develop robust prokaryotic or eu-
karyotic models for expressing perforin or its putative do-
mains. Some years ago, it was shown that rat basophil leu-
kemia (RBL) cells transfected to express perforin acquired
the capacity to lyse erythrocytes (16), whereas cells that co-
expressed perforin and granzyme B were able to kill some
nucleated target cells (17). However, these RBL transfec-
tants failed to express perforin in sufficient quantity, or ex-
pression was too unstable to enable ongoing studies. A fur-
ther study reported expression and partial purification of
perforin expressed in baculovirus-infected insect cells (18);
however, the yield was low and the recovered perforin was
denatured and had poor activity.
In the current study, we revisited perforin expression in
RBL cells and developed robust expression systems to in-
vestigate, for the first time, the molecular and cellular basis
for perforin dysfunction associated with two missense mu-
tations reported in an HLH patient. Our results indicate the
feasibility of using RBL-based and other perforin expres-
sion modalities to study both the basis of the HLH immune
deficiency and, more broadly, structure–function relation-
ships for perforin.
 
Materials and Methods
 
Cell Culture.
 
The cell lines RBL-2H3 cells (rat basophil leu-
kemia; American Type Culture Collection), which will be re-
ferred to in the text as RBL, and 293T (human embryonic kid-
ney) were maintained in DMEM medium supplemented with
10% FCS, 2 mM glutamine, and 100 
 
 
 
g/ml each of streptomycin
and penicillin in a humidified incubator at 37
 
 
 
C. Jurkat T cells
were maintained in RPMI-1640 medium supplemented as above.
RBL and 293T cells were detached from culture flasks using
trypsin-EDTA solution (CSL Ltd.) at 37
 
 
 
C.
 
Transient Transfection of RBL Cells.
 
Mature human and mouse
perforin each have 534 amino acids. However, the leader sequence
of human perforin is one amino acid longer than that of the mouse.
This results in a difference in conventional amino acid numbering
such that amino acids at positions 225 and 429 mutated in HLH
Patient #5 (11) correspond to residues 224 and 428 in the mouse
protein, as noted throughout Results and Discussion. Importantly,
arginine 225 is a nonconserved residue with threonine being
present in mouse perforin. To demonstrate the equivalence of argi-
nine and threonine at this position, we generated the T224R vari-
ant and, subsequently, the T224W mutant, which corresponds to
R225W in Patient #5 (11). The mutations were introduced using
the Transformer (Stratagene) site-directed mutagenesis system ac-
cording to the manufacturer’s instructions. The resultant and the
WT cDNA were cloned into the pIRES2-EGFP expression vector
(CLONTECH Laboratories, Inc.). Fc
 
 
 
 receptor–expressing RBL
cells were grown to near confluence in 175-cm
 
2
 
 flasks, harvested,
washed twice, and resuspended at 10
 
8 
 
cells/ml in serum-free
DMEM. 200 
 
 
 
L of the cell suspension was mixed with 20 
 
 
 
g
pIRES2-EGFP containing the WT or mutated perforin cDNA or
vector DNA alone, incubated at room temperature for 10 min, and
electroporated in 4-mm electroporation cuvettes and Bio-Rad
Laboratories pulser at 500 
 
 
 
F and 0.25 V. After 10 min at RT, the
cells were transferred into complete DMEM. Cells were harvested
18–20 h later, and GFP-expressing cells were sorted by flow cy-
tometry (FACStar; Beckton Dickinson).
 
Generation of Recombinant Retroviruses and Stable Expression of
Perforin in RBL Cells.
 
The missense perforin mutation, G428E,
corresponding to the human G429E (identified in another per-
forin allele in Patient #5; [reference 11]), was generated using the
Quick-Change site–directed mutagenesis system (Stratagene) ac-
cording to the manufacturer’s instructions. The cDNAs encoding
mouse WT and G428E perforin were subcloned into the retrovi-
ral expression vector MSCV, which contains an internal ribo-
some entry site for GFP expression (19). For retroviral transduc-
tion of RBL cells, viral supernatant was generated by cotransfecting
the MSCV plasmids with an amphotropic packaging plasmid into
293T cells by calcium phosphate precipitation. After 48 h, the vi-
ral supernatant was harvested and added to RBL cells every 12 h
for 3 d. The population of cells with the greatest GFP expression
(up to 5% of total cells) was subsequently purified by flow cytom-
etry and analyzed for perforin expression.
 
Assessing the Cytotoxicity of Transfected RBL Cells.
 
The cyto-
toxic capacity of RBL cells was analyzed using Jurkat T cell tar-
gets in a 4-h 
 
51
 
Cr release assay as described previously (16).
Briefly, the surface of 
 
51
 
Cr-labeled Jurkat cells was derivatized
with a 1 mM solution of trinitrobenzosulfonic acid in PBS, (pH
7.4) for 15 min at 37
 
 
 
C and washed with unsupplemented
DMEM three times. The transfected RBL cells were harvested
and incubated with antitrinitrophenol IgE mAb (2 
 
 
 
g/ml) at
37
 
 
 
C for 15 min and washed with unsupplemented DMEM three
times. RBL and Jurkat cells were coincubated at various effector
to target (E:T) ratios at 37
 
 
 
C in 200 
 
 
 
l serum-free DMEM sup-
plemented with 1% BSA for 4 h in 96-well plates. The superna-
tant was then harvested and the released 
 
51
 
Cr measured in a
gamma counter. The total 
 
51
 
Cr content of Jurkat cells was esti-
mated using 5% Triton X-100–lysed cells. The percentage-spe-
cific chromium release was calculated as 100
 
 
 
 ([experimental re-
lease 
 
 
 
 spontaneous release]/[total release – spontaneous release])
and is shown as mean 
 
 
 
 SD.
 
Isolation of Lysosomal Granules from RBL Cells.
 
Perforin was iso-
lated from 10
 
9
 
 stably expressing RBL cells by nitrogen cavitation
and Percoll density fractionation as described (20). To distinguish
granule-enriched fractions from other subcellular fractions, the
activity of the RBL granule marker enzyme, 
 
 
 
-hexosaminidase,
was measured as follows. 50 
 
 
 
L of each fraction was mixed with
30 
 
 
 
l 8 mM 
 
p
 
-nitrophenyl 
 
N
 
-acetyl-
 
 
 
-
 
d
 
-glucosaminide (Sigma-
Aldrich) and 10 
 
 
 
l 0.5 M sodium acetate, pH 5.0, at RT for 30
min. The reaction was stopped by adding 150 
 
 
 
l 50 mM NaOH,
and the absorbance was measured at 405 nm.
 
Expression of Recombinant Perforin and Membrane-binding Assay.
 
Perforin cDNA was cloned into the pFastBac vector and overex-
pressed in Sf-21 cells using a Back-to-Back kit (Invitrogen) and
perforin was purified, all according to the manufacturer’s instruc-
tions. Small amounts of recombinant WT and the G428E per-
forin mutant protein were obtained. To study the calcium-
dependent membrane binding of perforin, 2 
 
 
 
 10
 
7
 
 sheep RBCs
were resuspended in 200 
 
 
 
l 20 mM Hepes-150 mM NaCl buffer
(pH 7.4) supplemented with 1 mM CaCl
 
2
 
. An aliquot of the pu-
rified perforin was added to the cell suspension for 5 min on ice.
The cells were pelleted at 16,000 
 
g
 
 for 10 s, the supernatant
promptly removed, and the cells lysed in ice cold water. The ly-
sate was centrifuged for 20 min at 16,000 
 
g
 
 at 4
 
 
 
C. The pellet was 
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washed once, dissolved in SDS-PAGE loading buffer, and ana-
lyzed by Western blotting.
 
Immunoperoxidase Staining.
 
Approximately 1,000 RBL cells were
seeded in each well of an 8-well chamber slide 1 d before staining
and cultured overnight. In some experiments, cells were induced
to undergo degranulation by transient incubation with TNP-
labeled tumor target cells. The RBL cells were fixed for 10 min
at RT in 3.7% paraformaldehyde, washed three times in PBS,
permeabilized in 0.1% Triton X-100, 0.5% BSA for 5 min, and
then washed as before. The cells were treated with periodic acid
(0.5%) for 10 min, and endogenous peroxidase activity was
quenched with 0.3% H
 
2
 
O
 
2
 
 for 15 min. Blocking buffer (1%
BSA/1% skim milk powder in PBS) was added for 30 min before
the rat antiperforin mAb P1-8 (21). Bound Ig was detected with
biotinylated donkey anti–rat IgG (Jackson ImmunoResearch
Laboratories), streptavidin-HRP (Dako) for 10 min, and the
chromogen diaminobenzidine (Dako). Finally, cells were coun-
terstained with eosin and viewed by light microscopy.
 
Western Blotting.
 
Cell lysates from stable or transiently trans-
fected RBL cells or granule extracts were resolved on 10% SDS-
PAGE (Tris-Glycine) gels, transferred to PVDF membranes, and
assayed for perforin content using rat antiperforin mAb PI-8
(provided by Dr. Hideo Yagita, Juntendo Univeristy, Tokyo, Ja-
pan) (21) and anti–rat HRP-conjugated Ig. The signal was de-
tected using chemiluminescence (Amersham Biosciences).
 
Results and Discussion
 
In 
 
 
 
30% of cases, the severe immunodeficiency of HLH
has been attributed to mutations in the 
 
PFN1
 
 gene (11–13).
Although mutations that cause a frame-shift or premature
termination would be expected to abrogate perforin func-
tion, others result in single amino acid substitutions whose
effect on perforin function is unknown. The appreciation
that perforin mutations can result in immune dysfunction
offers a unique opportunity to characterize perforin struc-
ture–function relationships. To date, however, such studies
have been greatly hindered by a lack of appropriate meth-
odologies for expressing perforin in cells capable of granule-
mediated cytotoxicity. Perforin’s capacity to disrupt lipid
membranes means that few cell lines can accurately process
and store perforin in secretory vesicles and then release it in
Figure 1. Reduced cytotoxic
activity and truncation of T224W
mouse perforin expressed in RBL
cells. Perforin-dependent 51Cr re-
lease from TNP-labeled Jurkat
cells coincubated with transiently
transfected, sorted RBL cells for
4 h in the presence of anti-TNP
IgE. The data points are shown
as the mean   SD of triplicate
samples and are representative of
three similar assays. The Western
blot (right) shows truncation of
T224W perforin expressed in two
independent transfection experi-
ments (T224W-1 and T224W-2)
compared with WT and T224R
perforin.
 
a regulated fashion after conjugate formation. No appropri-
ate human cell lines exist to attempt such an analysis. How-
ever, standard transfection methodologies in RBL cells have
shown previously that perforin expression confers the ca-
pacity to lyse erythrocytes (16), whereas coexpression of
perforin and either granzyme A or B was necessary to effec-
tively kill nucleated cells (17). Despite this, perforin expres-
sion was not sufficiently stable in RBL cells to permit ongo-
ing studies. To address these issues, we revisited perforin
expression in RBL cells but applied efficient expression and
cell sorting technologies to compare the function of WT
and mutated perforin. For our analysis, we chose to study
HLH Patient #5, a compound heterozygote with perforin
missense mutations R225W and G429E (11,12). The R225W
mutation has also been identified in several unrelated indi-
viduals (13). We had shown previously that overexpressing
human perforin in rodent CTLs could disrupt the process-
ing of endogenous perforin, suggesting that human and ro-
dent perforin may be processed in subtly different ways (22).
Therefore, we introduced mutations equivalent to those of
P5 into mouse perforin and compared the function of these
molecules with WT mouse perforin.
We initially devised a rapid method for transient trans-
fection of RBL cells, using the vector pIRES2-EGFP. 1 d
after electroporation, fluorescent cells were sorted and im-
mediately used in a 
 
51
 
Cr release assay with Jurkat target cells
to which they were conjugated. The efficiency of elec-
troporation was as high as 40%, and up to 10
 
6
 
 GFP-express-
ing cells were obtained per electroporation. Although
G429 is conserved in human, mouse, and rat perforin,
R225 is not invariant and corresponds to T224 in mouse
perforin. To confirm the functional equivalence of arginine
and threonine at this position, we generated RBL cells ex-
pressing T224R mouse perforin and found they were as ef-
ficient in the 
 
51
 
Cr release assay as WT perforin-transfected
cells. However, expressing perforin with tryptophan at the
same position (T224W) resulted in complete loss of cy-
tolytic function (Fig. 1). As expected, the WT protein had
an apparent molecular mass of 
 
 
 
67 kD; however, the in-
troduction of tryptophan resulted in the appearance of trun- 
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cated (
 
 
 
45 kD) perforin (Fig. 1), suggesting the mutation
facilitated proteolytic cleavage/ processing of perforin. Fur-
thermore, immunohistochemistry analysis of transfected
cells indicated mislocalisation of T224W, possibly due to a
loss of putative signaling motif(s). Whereas WT perforin
produced a punctate appearance consistent with packaging
in secretory granules, T224W perforin produced diffuse
staining throughout the RBL cell cytoplasm (Fig. 2 A).
When we similarly analyzed the effect of the G428E
(G429E in humans) mutation co-inherited by Patient #5
(11), we observed a reduced level of 
 
51
 
Cr release compared
with RBL cells expressing WT perforin (unpublished data).
To accurately quantify this reduced activity, we produced
cell lines that stably expressed WT and G428E perforin.
Retrovirus-transduced RBL cells were analyzed on a flow
cytometer, and the most highly fluorescent cells (0.2–5% of
the total population) were sorted and expanded in culture
resulting in 
 
 
 
93% GFP-positive cells some days later. These
cells expressed perforin at levels equivalent to IL-18/IL-
21–activated mouse primary NK cells (Fig. 3 A). Perforin
expression and cytotoxic function remained stable over
many weeks of continuous culture (unpublished data).
Consistent with our transient transfection experiments,
RBL cells expressing WT perforin were efficient in lysing
Jurkat target cells across a broad range of E:T ratios (Fig. 3
B). To determine the difference in cytolytic activity be-
tween WT and G428E perforin, the E:T ratios required to
produce equivalent levels of 
 
51
 
Cr release were compared.
We found that RBL cells expressing similar levels of
G428E were three to four times less efficient at inducing
chromium release (Fig. 3 B).
We went on to investigate the reason for the reduced
cytotoxicity of G428E perforin. As demonstrated by im-
munoblotting (Fig. 3 B), this was not due to protein cleav-
age or degradation. To rule out incorrect trafficking to
secretory granules, we examined the intracellular localiza-
tion of WT and G482E perforin in stably transduced RBL
cells. Finding normal quantities of mutated perforin in the
granules would further exclude a significant defect in gene
transcription, mRNA stability or translation, or protein
folding. When lysates of RBL cells expressing WT or
G428E perforin were fractionated on a Percoll gradient and
analyzed by Western blot, perforin was consistently local-
ized in the fractions containing maximal 
 
 
 
-hexosamidase
activity, a marker of the lysosome-like secretory granules
(21) (Fig. 3 C). The correct targeting of perforin was also
confirmed through immunohistochemical staining, as both
WT and G428E perforin demonstrated indistinguishable
punctate cytoplasmic staining (Fig. 2 A). G428E perforin
was also released by exocytosis as efficiently as WT perforin
upon RBL Fc
 
 
 
 receptor cross-linking (Fig. 2 B).
Since G428E perforin was expressed at equivalent levels
to WT perforin and correctly targeted to, and released
from, granules (Fig. 2 and Fig. 3, B and C), the mutation
was likely to affect a postsynaptic function of perforin. To
test this possibility, we generated and purified recombinant
WT and G428E perforin using a baculovirus expression
system and tested their ability to bind to sheep RBC mem-
branes in a calcium-dependent manner. Whereas WT per-
forin displayed strong calcium-dependent plasma mem-
brane binding with essentially all the added perforin bound,
the binding of G428E perforin was markedly reduced (Fig.
4). Consistent with this observation, the cytolytic activity of
the recombinant G428E mutant was 
 
 
 
5% of that of WT
perforin (unpublished data). Although RBL cells have been
used as a read-out of perforin function for many years, a
perceived weakness of the model is that perforin exerts its
cytolytic effects in the absence of granzyme B. Exposure of
target cells to recombinant G428E-perforin with granzyme
B did not rescue the perforin phenotype (unpublished
data). Therefore, our findings strongly suggested that the
diminished activity of G428E-perforin was due to dimin-
ished target cell membrane binding, rather than the absence
of granzymes. Based on modeling studies and biochemical
analysis of CTL clones, Uellner and colleagues found that
Figure 2. T224W and G428E perforin localize differently in RBL
cells. (A) Immunohistochemistry of perforin-expressing RBL cells dem-
onstrated with antiperforin antibody PI-8 and counterstained with eosin.
(B) RBL cells either unlabeled or labeled with  -TNP–IgE were stained
as in A, after degranulation was induced by transient incubation with
TNP-labeled target cells. Magnification, 400 . 
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perforin’s COOH terminus strongly resembles that of cal-
cium-dependent membrane-binding C2 family of protein
domains, some of which are involved in vesicular traffick-
ing at neuronal synapses (23). Importantly, G428 is located
in the C2 domain of perforin, immediately adjacent to one
of five highly conserved aspartate residues believed to be es-
sential for calcium binding (23). We postulate that the
G428E substitution may interfere with calcium binding to
the C2 domain, leading to decreased affinity of perforin for
lipids in the target cell membrane (23). The apparent quan-
titative differences in G428E-perforin–induced cytolysis in
the RBL-based and recombinant models probably reflects
differences in the kinetics of perforin–target cell membrane
interaction in the context of a cell conjugate (RBL model)
and in solution (purified recombinant perforin).
This is the first study to successfully define the functional
basis of naturally occurring perforin mutations that when
co-inherited, lead to the catastrophic immunosuppression
seen in HLH. Surprisingly, we demonstrated that partial
Figure 3. Reduced cytotoxic
activity but normal apparent
molecular mass of G428E mouse
perforin expressed in RBL cells.
(A) Western blot showing perforin
expression in stably transduced
RBL cells compared with IL18/
IL-21–activated mouse NK cells
and empty vector-expressing cells
(GFP). (B) Perforin-dependent
51Cr release from TNP-labeled
Jurkat cells coincubated for 4 h in
the presence of anti-TNP IgE
with RBL cells stably expressing
WT or G428E perforin. The data
points are shown as the mean  
SD of three independent experi-
ments. The Western blot (right)
shows that G428E comigrates
with WT perforin. GFP is the
empty vector control. (C) RBL
cells stably overexpressing WT or
G428E perforin or the empty vec-
tor (GFP) were lysed and fraction-
ated on a Percoll density gradient.
Fractions were then analyzed for
their perforin content by Western
blotting and their  -hexosamini-
dase activity (as described in
Materials and Methods).
Figure 4. The G428E muta-
tion significantly reduces calcium-
dependent membrane binding of
soluble perforin. Equal quantities
of recombinant WT and mutant
perforin were tested for their ca-
pacity to bind to sheep erythro-
cytes in the absence ( ) or pres-
ence ( ) of 1 mM CaCl2. The
total input of perforin in each case
is shown as C. 
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loss of perforin function may be sufficient to bring about
fatal disease. Whereas the T224W mutation (corresponding
to R225W in humans) resulted in protein instability and
complete loss of RBL cytotoxic function, G428E (G429E
in humans) was only partially inactivating as RBL cells re-
tained 
 
 
 
25–30% of WT lytic activity. It is not clear
whether this substitution would lead to disease when in-
herited in the homozygous state; however, when com-
bined with the completely inactive R225W allele, the
overall cytolytic activity of perforin appears to be insuffi-
cient to rescue the patient. Based on the result of our RBL
assays, one could predict that CTL expressing equal quanti-
ties of T224W- and G428E-perforin would have some re-
sidual but markedly reduced cytotoxic activity. In fact, the
NK cells of Patient #5 did exhibit 
 
 
 
15% lytic activity of
control samples (11,12). The concordance of our data with
the clinical findings in this case provides evidence that our
experimental approaches should provide a robust basis for
understanding other perforin mutations identified in HLH.
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